Navigation Links
Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 2011
Date:8/23/2010

SAN DIEGO, Aug. 23 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today that based on solid bookings and sales activities in July and the first half of August that it expects its net sales for its second quarter of fiscal 2011 ending September 30, 2010, to be from $2.8 to $3.2 million, an increase of 158% to 195% compared to the first quarter of fiscal 2011 and 47% to 68% compared to the second quarter of the previous fiscal year.

"The first two months of our September ending quarter have progressed nicely as a result of shipments and bookings of our branded products in the mass market, Celadrin® and BioGuard®.  In addition BioGuard® is scheduled to be introduced at a major drug chain expanding its outreach beyond club stores," said William Spencer, Imagenetix's President and CEO. "We are not currently providing guidance on income, but expect with the significant increase in net sales that we will return to profitability.  We continue to see excellent acceptance of our products and believe we are positioned well for future revenue gains."

Cautionary Statement:The statements in this release relating to our guidance for net sales, profitability, and our being positioned for future revenue gains are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause our actual results to differ materially, including, but not limited to: the strength of the economic recovery or any further weakness or unexpected fluctuations in the U.S. or global economies; changes in demand or market acceptance of our products and the products of our customers; the mix of inventory we hold and our ability to satisfy short-term orders from our inventory; changes in utilization of our manufacturing capacity and our ability to effectively ramp our production levels; competitive developments including pricing pressures; the level of orders that are received and can be shipped in a quarter; the level of sell-through of our products through distribution; changes or fluctuations in customer order patterns and seasonality; disruptions in our business or the businesses of our customers or suppliers due to natural disasters, terrorist activity, armed conflict, war, worldwide oil prices and supply, public health concerns or disruptions in the transportation system; and general economic, industry or political conditions in the United States or internationally.

For a detailed discussion of these and other risk factors, please refer to Imagenetix's filings on Forms 10-K and 10-Q. You can obtain copies of Forms 10-K and 10-Q and other relevant documents for free at the SEC's Web site (www.sec.gov) or from commercial document retrieval services.

Stockholders of Imagenetix are cautioned not to place undue reliance on our forward-looking statements, which speak only as of the date such statements are made. Imagenetix does not undertake any obligation to publicly update any forward-looking statements to reflect events, circumstances or new information after this August 23, 2010 press release, or to reflect the occurrence of unanticipated events.

About ImagenetixImagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis.  Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution.  In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners.  Imagenetix is the creator of Celadrin®.  Please visit, www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net. ContactImagenetix Investor Relations

William P. Spencer(858)385-2797

Chief Executive OfficerImagenetix, Inc.Tel: (858) 674-8455
'/>"/>

SOURCE Imagenetix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Letter to Shareholders From Imagenetix, Inc. President/CEO William Spencer
2. Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia
3. JumpStart Ventures Invests In and Provides Entrepreneurial Assistance to Drug Development Company
4. PharmAthene Provides Update on NYSE Amex Listing Compliance Plan
5. New FDLI Monograph Provides Expert Guidance on Selling Pharmaceuticals, Biologics to Federal Government
6. China Nepstar Chain Drugstore Provides Updates on Shoppers Card Program
7. Newly Published Data Demonstrate ASP EVOTECH® ECR Provides Cleaning That is Superior to Manual Cleaning of Flexible Endoscopes
8. Mindray Medical Provides Mid-Year Update on Product Development
9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
10. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
11. Purdue Pharma L.P. Provides Free Security Mobiles and Educational Safety Videos to Good Neighbor Pharmacy Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
Breaking Medicine News(10 mins):